|
Jan 3
|
Top 5 Momentum Picks for January After a Fabulous 2023
|
|
Jan 1
|
A Look At The Intrinsic Value Of BeiGene, Ltd. (NASDAQ:BGNE)
|
|
Dec 28
|
12 High Growth International Stocks to Buy
|
|
Dec 22
|
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
|
|
Dec 21
|
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
|
|
Dec 21
|
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 19
|
13 Most Promising Healthcare Stocks According to Analysts
|
|
Dec 19
|
5 Nasdaq Composite Laggards Likely to Gather Pace in 2024
|
|
Dec 4
|
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
|
|
Nov 30
|
Wall Street Analysts Think BeiGene, Ltd. (BGNE) Could Surge 44.28%: Read This Before Placing a Bet
|
|
Nov 29
|
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
|
|
Nov 28
|
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
|
|
Nov 8
|
BeiGene to Present at the Jefferies London Healthcare Conference
|
|
Nov 2
|
BeiGene, Ltd.'s (NASDAQ:BGNE) one-year returns climbed after last week's 8.9% gain, institutional investors must be happy
|
|
Jul 14
|
Ray Dalio’s China Stocks
|
|
Jul 13
|
Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?
|